Clinical trials: Urothelial Tract/Bladder Cancer, Nos
Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Urothelial Carcinoma
INJECT: A Pilot Study of Intra-tumoral Injections in Metastatic Urological Cancers
The purpose of this study is to plan for future clinical trials in patients with metastatic urological cancers. Diluted iodinated contrast will be injected intra-tumorally under CT fluoroscopy guidance into bone, lymph node, soft…
- Conditions
- Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Urothelial Carcinoma, Metastatic Renal Cell Carcinoma
- Trial name
- NCT03071328
- Testing
- Isovue-M 200
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Duke University
Urologic Cancer
Clinical Evaluation of ExoDx Prostate(IntelliScore) in Men Presenting for Initial Prostate Biopsy
The study described here is being conducted to prospectively confirm the performance of the ExoDx Prostate gene expression assay in patients presenting for an initial prostate biopsy and support of CE-marking the test for a…
- Trial name
- NCT04720599
- Testing
- ExoDx Prostate(IntelliScore)
- Where
- 3 sites in United States, Germany
- Volunteers
- 120 people
- Sponsor
- Exosome Diagnostics, Inc.
Urinary Tract Cancer
A Study of Herceptin (Trastuzumab) Monotherapy in Patients With Metastatic Urothelial Cancer
This study will evaluate the efficacy and safety of intravenous Herceptin in patients with metastatic urothelial cancer with disease progression during platinum-based chemotherapy.
- Trial name
- NCT02013765
- Testing
- trastuzumab
- Where
- 7 sites in Germany
- Volunteers
- 5 people
- Sponsor
- Hoffmann-La Roche
Solid Tumors
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
This is a Phase 1, open-label, dose-escalation trial of avelumab [antibody targeting programmed death ligand 1 (anti PD-L1)] with consecutive parallel group expansion in participants with selected tumor indications.
- Trial name
- NCT01772004
- Testing
- Avelumab
- Where
- 74 sites in United States, Belgium and 7 more
- Volunteers
- 1,756 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Advanced Solid Cancers
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
The main goal of this study is to evaluate the safety of BNT329 and to identify the best dose of BNT329. This will be done by measuring the number of side effects that participants experience and how severe they are.
- Trial name
- NCT07186842
- Testing
- BNT329, CA19-9-targeting monoclonal antibody
- Where
- 18 sites in United States, Australia and 3 more
- Volunteers
- 245 people
- Sponsor
- BioNTech SE
Metastatic Cancer, Solid Tumors
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
This study is an open-label Phase 1/Phase 2 evaluation of INCB001158 as a single agent and in combination with immune checkpoint therapy in patients with advanced/metastatic solid tumors.
- Conditions
- Metastatic Cancer, Solid Tumors, Colorectal Cancer (CRC), Gastric Cancer
- Trial name
- NCT02903914
- Testing
- INCB001158, Pembrolizumab
- Where
- 20 sites in United States, Italy and 2 more
- Volunteers
- 260 people
- Sponsor
- Incyte Corporation
Prostate Cancer Metastatic, Radiotherapy Side Effect
Metastatic Prostate Cancer Men's Attitudes Towards Treatment of the Local Tumour and Metastasis Evaluative Research
Systemic therapy (i.e Androgen Deprivation Therapy with Docetaxel, Enzalutamide, Apalutamide or Abiraterone Acetate) has increased overall survival in men with hormone-sensitive metastatic prostate cancer.
- Conditions
- Prostate Cancer Metastatic, Radiotherapy Side Effect, Surgery, Urologic Cancer
- Trial name
- IP5-MATTER (NCT04590976)
- Testing
- Semi-Structured Interview Healthcare Professional, Semi-Structured Interview Patients, Think Aloud Interview Patients
- Where
- 35 sites in United Kingdom
- Volunteers
- 320 people
- Sponsor
- Imperial College London
Cancer Cachexia, Omega 3
Effects of Dietary Supplementation With omega3-fatty Acids (Fish Oil) and Progressive Resistance Training on Skeletal Muscle Status in Gynaecological, Gastrointestinal and Urological Cancer Patients
Cancer cachexia is a common and prognostically relevant complication of advanced malignancies, characterized by systemic inflammation, increased catabolism, and reduced nutritional intake, leading to a progressive loss of…
- Conditions
- Cancer Cachexia, Omega 3, Resistance Training, Cancer
- Trial name
- SUPPORT (NCT07643558)
- Testing
- Omega 3 FA (Fish Oil), Training
- Where
- Germany
- Volunteers
- 288 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Advanced Solid Tumor, Metastatic Cancer
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007, also known as imneskibart, in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer
- Trial name
- NCT05267626
- Testing
- AU-007, Aldesleukin, Avelumab
- Where
- 17 sites in United States, Australia
- Volunteers
- 159 people
- Sponsor
- Aulos Bioscience, Inc.
Amyloidosis, Basal Cell Carcinoma
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
This phase II trial studies whether providing cancer treatment in the home is preferred over the traditional clinic setting and if it improves treatment satisfaction in cancer patients living in the Florida Panhandle and…
- Conditions
- Amyloidosis, Basal Cell Carcinoma, Biliary Tract Carcinoma, Bladder Carcinoma
- Trial name
- NCT07285044
- Testing
- Cancer Therapeutic Procedure, Questionnaire Administration
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Mayo Clinic
Prostate Carcinoma, Kidney Cancer
Development of Diagnostics and Treatment of Urological Cancers
The purpose of the study is to evaluate whether state-of-the-art technologies such and next generation sequencing and drug sensitivity and resistance testing of patient derived tumour tissue can facilitate research translation…
- Conditions
- Prostate Carcinoma, Kidney Cancer, Urothelial Carcinoma, Testicular Cancer
- Trial name
- DEDUCER (NCT02994758)
- Testing
- Personalised treatment
- Where
- Finland
- Volunteers
- 100 people
- Sponsor
- Helsinki University Central Hospital
Smoking Cessation, Smoking Reduction
Preoperative Smoking Cessation in Patients Undergoing Surgery
Background: At present, effectively implementing smoking cessation programs in the health care system constitutes a major challenge. A unique opportunity to initiate smoking cessation focuses on smokers scheduled for surgery.
- Conditions
- Smoking Cessation, Smoking Reduction, Surgery--Complications, Surgery
- Trial name
- PORTICO (NCT05192837)
- Testing
- Intensive preoperative smoking cessation counselling
- Where
- Switzerland
- Volunteers
- 251 people
- Sponsor
- Luzerner Kantonsspital
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
SCH 66336 Plus Gemcitabine in Treating Patients With Advanced Cancer of the Urinary Tract
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining SCH 66336 and gemcitabine may kill more tumor cells.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00006351
- Testing
- gemcitabine hydrochloride, lonafarnib
- Where
- Netherlands
- Volunteers
- 34 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Urinary Tract Cancer
A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract
This Phase IIIb, multicenter study will assess the safety of atezolizumab as second- to fourth-line treatment for participants with locally advanced or metastatic urothelial or non-urothelial cancer of the urinary tract in…
- Trial name
- NCT02928406
- Testing
- Atezolizumab
- Where
- 175 sites in Argentina, Australia and 30 more
- Volunteers
- 1,004 people
- Sponsor
- Hoffmann-La Roche
Squamous Cell Carcinoma, Urinary Tract Cancer
Atezolizumab Immunotherapy, in Immunotherapy Naive Patients With Urinary Tract Squamous Cell Carcinoma (UTSCC).
Atezolizumab in patients with urinary tract squamous cell carcinoma: a single-arm, open-label, multicentre, phase II clinical trial
- Trial name
- AURORA (NCT05038657)
- Testing
- Atezolizumab
- Where
- United Kingdom
- Volunteers
- 36 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Urological Cancer, Gastrointestinal Cancer
Correlation Between Intraocular Pressure Measurement by Tomometer and Anterior Chamber Depth Measurement by Ultrasound
Intra ocular pressure (IOP) may theoretically increase due to steep Trendelenberg position and studies showed that IOP reaches peak levels after steep Trendelenberg position on an average of 13 mmHg higher than preanesthesia…
- Conditions
- Urological Cancer, Gastrointestinal Cancer, Malignant Female Reproductive System Neoplasm
- Trial name
- NCT02818530
- Testing
- IOP by tonometer, Anterior chamber depth measurement by ultrasound
- Where
- India
- Volunteers
- 10 people
- Sponsor
- Tata Memorial Centre
Bladder Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma
Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer
Objectives: Primary: Safety and tolerability of therapy with daratumumab in a cohort of patients with metastatic renal cell carcinoma and a cohort of patients with muscle invasive bladder cancer. Secondary: 1A.
- Conditions
- Bladder Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma, Malignant Urinary System Neoplasm, Metastatic Kidney Carcinoma
- Trial name
- NCT03473730
- Testing
- Biopsy, Daratumumab, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- M.D. Anderson Cancer Center
Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)
A Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line Therapy
This is a Phase 3, open-label single-arm trial designed to evaluate the safety and efficacy of NDV-01 (sustained-release gemcitabine-docetaxel) in adult participants with NMIBC with CIS who have failed BCG therapy and who have…
- Conditions
- Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent
- Trial name
- RESCUE (NCT07342517)
- Testing
- NDV-01 (sustained-release gemcitabine-docetaxel)
- Volunteers
- healthy volunteers welcome
- Sponsor
- Relmada Therapeutics, Inc.
Solid Tumors, Head and Neck Carcinoma
Milademetan in Advanced/Metastatic Solid Tumors
Phase 2, multicenter, single-arm, open-label basket study designed to evaluate the safety and efficacy of milademetan in patients with advanced or metastatic solid tumors refractory or intolerant to standard-of-care therapy that…
- Conditions
- Solid Tumors, Head and Neck Carcinoma, Cholangiocarcinoma, Sarcoma
- Trial name
- NCT05012397
- Testing
- RAIN-32
- Where
- 14 sites in United States
- Volunteers
- 40 people
- Sponsor
- Rain Oncology Inc
Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
This clinical trial is evaluating a drug called BT5528 alone and in combination with nivolumab in participants with advanced solid tumors historically known for expression of EphA2.
- Conditions
- Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer, Ovarian Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT04180371
- Testing
- BT5528, Nivolumab
- Where
- 28 sites in United States, Belgium and 3 more
- Volunteers
- 288 people
- Sponsor
- BicycleTx Limited